Non Hodgkin's Lymphoma Clinical Trials
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Recruiting
- Leukemia
- +4 more
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022N
Recruiting
- Myelodysplastic Syndrome
- +4 more
- Rituximab
- +6 more
- Bethesda, Maryland
- +1 more
2022-04-07
Apr 7, 2022N
Recruiting
- Non-Hodgkin's Lymphoma
- +3 more
- DA-EPOCH
- +3 more
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022N
Recruiting
- Follicular Lymphoma
- +2 more
- Rituximab
- Copanlisib
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022E
H
Active, not recruiting
- Non-Hodgkin's Lymphoma
- Obinutuzumab
- +3 more
- Tucson, Arizona
- +22 more
2022-04-06
Apr 6, 2022O
Recruiting
- Acute Lymphoblastic Leukemia
- +2 more
- CLIC-1901
- Vancouver, British Columbia, Canada
- +1 more
2022-03-26
Mar 26, 2022N
Completed
- Chronic Myelogenous Leukemia
- +9 more
- Fludarabine
- +3 more
- Atlanta, GeorgiaNorthside Hospital
2022-04-04
Apr 4, 2022A
Active, not recruiting
- CD20-Positive Lymphoid Malignancies
- +3 more
- Tucson, Arizona
- +5 more
2022-03-22
Mar 22, 2022L
Recruiting
- Non-Hodgkin's Lymphoma
- RiTUXimab Injection [Truxima]
- Vitoria-Gasteiz, Alava, SpainHospital Universitario Araba- Sede Txagorritxu
2022-03-30
Mar 30, 2022A
Recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- Phoenix, Arizona
- +30 more
2022-03-28
Mar 28, 2022S
Terminated
- Acute Myelogenous Leukemia
- +2 more
- Fenretinide
- +2 more
- Oklahoma City, Oklahoma
- +1 more
2022-03-17
Mar 17, 2022A
Available
- Chronic Lymphocytic Leukemia (CLL)
- +6 more
- (no location specified)
2022-03-28
Mar 28, 2022H
Recruiting
- Non-Hodgkin's Lymphoma
- Glofitamab
- +2 more
- Los Angeles, California
- +40 more
2022-03-24
Mar 24, 2022U
Active, not recruiting
- Non-Hodgkin's Lymphoma
- Hodgkin's Lymphoma
- CAR.CD30 T cells
- Chapel Hill, North Carolina
- +2 more
2022-03-16
Mar 16, 2022C
Completed
- Non-hodgkin's Lymphoma
- Beijing, Beijing, ChinaBeijing Cancer Hospital
2022-03-07
Mar 7, 2022M
Recruiting
- Diffuse Large B-cell Lymphoma
- +2 more
- Buffalo, New York
- +3 more
2022-03-01
Mar 1, 2022W
Active, not recruiting
- Acute Myelogenous Leukemia
- +10 more
- BL-8040
- +2 more
- Atlanta, Georgia
- +2 more
2022-02-09
Feb 9, 2022J
Recruiting
- Non-Hodgkin's Lymphoma
- single dose of CNCT19
- Fuzhou, Fujian, China
- +17 more
2022-02-17
Feb 17, 2022B
Active, not recruiting
- Non-Hodgkin's Lymphoma
- +2 more
- Nivolumab
- +5 more
- Clovis, California
- +30 more
2022-01-27
Jan 27, 2022B
Recruiting
- Non-Hodgkin's Lymphoma
- +2 more
- CD19.CAR-CD28Z T Cells - dose escalation 2
- CD19.CAR-CD28Z T Cells - dose escalation 1
- Houston, Texas
- +1 more
2022-02-10
Feb 10, 2022B
Active, not recruiting
- Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma
- autologous CAR.CD30 EBV specific-CTLs
- Houston, Texas
- +1 more
2022-02-04
Feb 4, 2022A
Recruiting
- Malignancies
- +4 more
- San Francisco, California
- +30 more
2022-01-31
Jan 31, 2022H
Recruiting
- Non-hodgkin's Lymphoma
- CD19+22 CAR-T cells
- Langfang, Hebei, ChinaHebei Yanda Ludaopei Hospital
2022-01-11
Jan 11, 2022M
Active, not recruiting
- Leukemia
- +3 more
- Palifermin
- +6 more
- New York, New YorkMemorial Sloan Kettering Cancer Center
2022-01-21
Jan 21, 2022